<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bicuspid Valve Archives - Heart Valve Voice US</title>
	<atom:link href="https://www.heartvalvevoice-us.org/tag/bicuspid-valve/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.heartvalvevoice-us.org/tag/bicuspid-valve/</link>
	<description>Giving a voice to people with heart valve disease</description>
	<lastBuildDate>Tue, 15 Jun 2021 15:54:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>

<image>
	<url>https://www.heartvalvevoice-us.org/wp-content/uploads/2019/02/cropped-Favicon-32x32.png</url>
	<title>Bicuspid Valve Archives - Heart Valve Voice US</title>
	<link>https://www.heartvalvevoice-us.org/tag/bicuspid-valve/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>New Developments Expected in 2019 for Minimally Invasive Valve Treatments</title>
		<link>https://www.heartvalvevoice-us.org/new-developments-expected-in-2019/</link>
		
		<dc:creator><![CDATA[Erin Fedorchak]]></dc:creator>
		<pubDate>Thu, 03 Jan 2019 01:10:02 +0000</pubDate>
				<category><![CDATA[Policy Archives]]></category>
		<category><![CDATA[Aortic Valve]]></category>
		<category><![CDATA[Bicuspid Valve]]></category>
		<category><![CDATA[Clinical Trial]]></category>
		<category><![CDATA[Mitral Valve]]></category>
		<category><![CDATA[Treatments]]></category>
		<guid isPermaLink="false">https://hvvprod.wpengine.com/?p=7152</guid>

					<description><![CDATA[<p>Mitral Valve Positive Findings A minimally-invasive treatment option for mitral valve regurgitation got a recent boost from a study finding fewer post-treatment hospitalizations for heart failure and also fewer deaths for all reasons. Abbott’s MitraClip is available for patients who are considered high risk for surgery. The valve is third generation technology and is delivered [&#8230;]</p>
<p>The post <a href="https://www.heartvalvevoice-us.org/new-developments-expected-in-2019/">New Developments Expected in 2019 for Minimally Invasive Valve Treatments</a> appeared first on <a href="https://www.heartvalvevoice-us.org">Heart Valve Voice US</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
